Using advanced test to detect precursor of esophageal cancer

Florida Digestive Health Specialists, the largest private practice gastroenterology network in the state, recently completed the first EsoCheck® procedures in Florida.

EsoCheck, developed by Lucid Diagnostics, is a device that collects cells from the lower esophagus without the need for endoscopy. The sampled cells can then be analyzed for DNA changes indicative of Barrett’s esophagus and esophageal cancer using a first-of-its-kind genomic test known as EsoGuard®.

“Most patients at risk for esophageal adenocarcinoma never or rarely get symptoms,” said Dr. Scott Corbett, gastroenterologist and director of the Barrett’s Esophagus Institute at Florida Digestive Health Specialists. “This technology gives us an opportunity to find many of the 94-95 percent of patients who are at risk for developing esophageal cancer but don’t know it.”

During a simple, in-office procedure, the patient swallows the vitamin-sized EsoCheck device, which contains a small inflatable balloon attached to a thin catheter. The balloon is then inflated and gently pulled back, swabbing the target area for a sample of cells, which are tested for biomarkers that have been shown to be highly accurate in detecting Barrett’s Esophagus, the primary precursor to the most common and deadly form of esophageal cancer.

“Watching Barrett’s esophagus through endoscopic surveillance is no longer our only option,” said Dr. Corbett, “People don’t need to die from this disease.”

Call to learn more about EsoCheck: 941.365.6556

About Barrett’s esophagus:
  • Barrett’s esophagus is a condition in which the lining of the esophagus changes to lining similar to that of the small intestine. In some patients, such modification is precancerous and carries an increased risk of developing esophageal cancer.
  • The primary cause for Barrett’s esophagus is chronic inflammation resulting from Gastroesophageal Reflux Disease (GERD). Barrett’s esophagus is more common in people who have had GERD for a long period of time or who developed it at a young age.
  • It is estimated that approximately 3 million people in the U.S. have Barrett’s esophagus. GERD affects an estimated 25-35% of the U.S. population
  • 10-20% of patients with chronic GERD symptoms have Barrett’s esophagus
  • 82% of people with esophageal cancer die within 5 years of their diagnosis
  • There will be an estimated 19,260 diagnoses and 15,530 deaths in 2021 from esophageal adenocarcinoma.
  • Barrett’s esophagus is twice as common in men than in women, and usually targets Caucasian men over the age of 50 who have had heartburn for many years.